| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f34119b232d292c72e632b62008eca90 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-203
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-008 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2004-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42ffdfb8933b46f25e49d595bf6e59eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1ef08dba74cd7c465691de7a3a04d9e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6e2b4da7d323941903456be4bce7ffe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e40f8f5b9738d1ed753e89291f4c9c24 |
| publicationDate |
2006-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1697536-A2 |
| titleOfInvention |
Novel oligonucleotides and treating cardiac disorders by using the same |
| abstract |
Novel oligonucleotides and methods of treating a cardiac disease or disorder using the same are provided. The oligonucleotides are useful in modulating the expression of the connexin 43 protein and may be combined with other biologically active agents and compositions to treat cardiac disease. Methods of modulating connexin expression include the suppression of the expression of connexin 43 and the inducement of expression of connexin 45. |
| priorityDate |
2003-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |